Search

Displaying results 2831 - 2840 of 9670 in total
  1. Drug

    Ormeloxifene

    go.drugbank.com/drugs/DB13310
    Experimental

    Ormeloxifene is a third-generation selective estrogen receptor (ER) modulator. … In India, ormeloxifene has been marketed since the 1990s as a non-hormonal, non-steroidal oral contraceptive taken once a week,[A251450] and it was later introduced for the treatment of dysfunctional uterine

  2. Drug

    Crizanlizumab

    go.drugbank.com/drugs/DB15271
    ApprovedInvestigational

    It was developed by Novartis and was granted FDA approval on November 15, 2019. … [T734] Currently, patients are prescribed [hydroxyurea] to raise levels of fetal hemoglobin as a method of reducing morbidity and mortality.

  3. Drug

    Mitotane

    go.drugbank.com/drugs/DB00648
    ApprovedInvestigational

    It has been in use since 1959 for the treatment of inoperable adrenocortical carcinoma[A263010] and is used off-label for the management of Cushing's syndrome.[A263016]

  4. Drug

    Methsuximide

    go.drugbank.com/drugs/DB05246
    Approved

    It is sold by Pfizer under the name Petinutin.

  5. Drug

    Quinine

    go.drugbank.com/drugs/DB00468
    ApprovedInvestigational

    It was used commonly and as a bitter and flavoring agent, and is still useful for the treatment of babesiosis. … It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633.

  6. Drug

    Paramethadione

    go.drugbank.com/drugs/DB00617
    Approved

    It is associated with fetal trimethadione syndrome, which is also known as paramethadione syndrome.

  7. Drug

    Tolrestat

    go.drugbank.com/drugs/DB02383
    ApprovedWithdrawn

    While it was approved for marketed in several countries, it failed a Phase III trial in the U.S. due to toxicity and never received FDA approval. … It was sold under the tradename Alredase but was discontinued by Wyeth in 1997 because of the risk of severe liver toxicity and death.

  8. Drug

    Miocamycin

    go.drugbank.com/drugs/DB13287
    Approved

    This drug may be marketed in Japan for clinical use as it is listed in the Japanese pharmacopeia [L5737]. … It has shown to be effective against several gram-positive and gram-negative microbes and may be useful in the treatment of upper and lower respiratory tract infections, and urogenital tract infections

  9. Drug

    Seladelpar

    go.drugbank.com/drugs/DB12390
    ApprovedInvestigational

    [L51149] On August 14, 2024, seladelpar was granted accelerated approval by the FDA for the treatment of primary biliary cholangitis,[L51154] which is a condition associated with aberrant bile acid metabolism

  10. Drug

    Potassium cation

    go.drugbank.com/drugs/DB01345
    Approved

    The ability of cells to produce electrical discharge is critical for body functions such as neurotransmission, muscle contraction, and heart function. … The concentration differences of these charged particles causes a difference in electric potential between the inside and outside of cells, known as the membrane potential.